Thermo Fisher Scientific (TMO) 10-Q 7 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Apr. 03, 2021shares
Entity Listings [Line Items]
Entity Central Index Key	0000097745
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 3, 2021
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	393,027,886
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 5,583	$ 10,325
Accounts receivable, less allowances of $143 and $135	5,554	5,741
Inventories	4,342	4,029
Contract assets, net	783	731
Other current assets	1,423	1,131
Total current assets	17,685	21,957
Property, Plant and Equipment, Net	6,133	5,912
Acquisition-related Intangible Assets, Net	12,831	12,685
Other Assets	2,459	2,457
Goodwill	26,823	26,041
Total Assets	65,931	69,052
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	4	2,628
Accounts payable	2,146	2,175
Accrued payroll and employee benefits	1,314	1,916
Contract liabilities	1,396	1,271
Other accrued expenses	2,135	2,314
Total current liabilities	6,995	10,304
Deferred Income Taxes	1,885	1,794
Other Long-term Liabilities	3,352	3,340
Long-term Obligations	18,641	19,107
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 437,622,084 and 437,088,297 shares issued	438	437
Capital in excess of par value	15,684	15,579
Retained earnings	30,350	28,116
Treasury stock at cost, 44,594,198 and 40,417,789 shares	(8,852)	(6,818)
Accumulated other comprehensive items	(2,562)	(2,807)
Total shareholders' equity	35,058	34,507
Total Liabilities and Shareholders' Equity	$ 65,931	$ 69,052

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 143	$ 135
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	437,622,084	437,088,297
Treasury Stock at Cost (in shares)	44,594,198	40,417,789

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Revenues
Revenues	$ 9,906	$ 6,230
Costs and Operating Expenses:
Selling, general and administrative expenses	1,826	1,551
Research and development expenses	320	245
Restructuring and other costs	14	38
Total costs and operating expenses	6,857	5,324
Operating Income	3,049	906
Interest Income	12	36
Interest Expense	(125)	(126)
Other (Expense) Income	(183)	12
Income Before Income Taxes	2,753	828
Provision for Income Taxes	(416)	(40)
Net Income	$ 2,337	$ 788
Earnings per Share
Basic (in dollars per share)	$ 5.93	$ 1.99
Diluted (in dollars per share)	$ 5.88	$ 1.97
Weighted Average Shares
Basic (in shares)	394	397
Diluted (in shares)	397	400
Product [Member]
Revenues
Revenues	$ 7,856	$ 4,630
Costs and Operating Expenses:
Cost of revenues	3,327	2,340
Service [Member]
Revenues
Revenues	2,050	1,600
Costs and Operating Expenses:
Cost of revenues	$ 1,370	$ 1,150

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Comprehensive Income
Net income	$ 2,337	$ 788
Currency translation adjustment:
Currency translation adjustment (net of tax provision of $118 and $22)	224	(357)
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0 and $19)	0	(62)
Reclassification adjustment for losses included in net income (net of tax benefit of $4 and $1)	13	1
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax benefit (provision) of $(2) and $(5))	6	5
Amortization of net loss included in net periodic pension cost (net of tax benefit of $1 and $1)	2	4
Total other comprehensive items	245	(409)
Comprehensive Income	$ 2,582	$ 379

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 118	$ 22
Tax benefit on unrealized holding losses on hedging instruments arising during the period	0	19
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	4	1
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	(2)	(5)
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 1	$ 1

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Operating Activities
Net income	$ 2,337	$ 788
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	198	149
Amortization of acquisition-related intangible assets	423	425
Change in deferred income taxes	24	(41)
Loss on early extinguishment of debt	197	0
Stock-based compensation	51	46
Other non-cash expenses, net	69	64
Changes in assets and liabilities, excluding the effects of acquisitions	(1,321)	(1,075)
Net cash provided by operating activities	1,978	356
Investing Activities
Acquisitions, net of cash acquired	(1,343)	(4)
Purchase of property, plant and equipment	(628)	(253)
Proceeds from sale of property, plant and equipment	5	4
Other investing activities, net	(32)	(7)
Net cash used in investing activities	(1,998)	(260)
Financing Activities
Net proceeds from issuance of debt	0	2,185
Repayment of debt	(2,804)	(1)
Proceeds from issuance of commercial paper	0	382
Repayments of commercial paper	0	(321)
Purchases of company common stock	(2,000)	(1,500)
Dividends paid	(87)	(76)
Net proceeds from issuance of company common stock under employee stock plans	20	48
Other financing activities, net	21	(98)
Net cash (used in) provided by financing activities	(4,850)	619
Exchange Rate Effect on Cash	137	(127)
(Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	(4,733)	588
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	10,336	2,422
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 5,603	$ 3,010

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2019			434				36
Balance at Dec. 31, 2019	$ 29,675	$ (1)	$ 434	$ 15,064	$ 22,092	$ (1)	$ (5,236)	$ (2,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				0
Issuance of shares under employees' and directors' stock plans	48		$ 1	76			$ (29)
Stock-based compensation	46			46
Purchases of company common stock (in shares)							4
Purchases of company common stock	(1,500)						$ (1,500)
Dividends declared	(88)				(88)
Net income	788				788
Other comprehensive items	(409)							(409)
Balance (in shares) at Mar. 28, 2020			435				40
Balance at Mar. 28, 2020	28,559		$ 435	15,186	22,791		$ (6,765)	(3,088)
Balance (in shares) at Dec. 31, 2020			437				40
Balance at Dec. 31, 2020	34,507		$ 437	15,579	28,116		$ (6,818)	(2,807)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				1
Issuance of shares under employees' and directors' stock plans	21		$ 1	54			$ (34)
Stock-based compensation	51			51
Purchases of company common stock (in shares)							4
Purchases of company common stock	(2,000)						$ (2,000)
Dividends declared	(103)				(103)
Net income	2,337				2,337
Other comprehensive items	245							245
Balance (in shares) at Apr. 03, 2021			438				45
Balance at Apr. 03, 2021	$ 35,058		$ 438	$ 15,684	$ 30,350		$ (8,852)	$ (2,562)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.26	$ 0.22

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Apr. 03, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at April 3, 2021, the results of operations for the three-month periods ended April 3, 2021 and March 28, 2020, and the cash flows for the three-month periods ended April 3, 2021 and March 28, 2020. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet presented as of December 31, 2020, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2020 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2020 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended April 3, 2021. Inventories The components of inventories are as follows: April 3, December 31, (In millions) 2021 2020 Raw Materials $ 1,491 $ 1,305 Work in Process 602 540 Finished Goods 2,249 2,184 Inventories $ 4,342 $ 4,029 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The extent and duration of negative impacts continuing into the remainder of 2021 are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial

Acquisitions

Acquisitions	3 Months Ended
	Apr. 03, 2021
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Proposed Acquisition On April 15, 2021, the company entered into a definitive agreement under which it will acquire PPD, Inc. for $47.50 per share for a total cash purchase price of $17.4 billion plus the assumption of approximately $3.5 billion of net debt. PPD provides a broad range of clinical research and specialized laboratory services to enable customers to accelerate innovation and increase drug development productivity. Upon close of the transaction, PPD will become part of the Laboratory Products and Services Segment. The transaction, which is expected to be completed by the end of 2021, is subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals. Shareholders holding in aggregate approximately 60% of the issued and outstanding shares of common stock of PPD have approved the transaction by written consent. No further action by other PPD shareholders is required to approve the transaction. 2021 On January 15, 2021, the company acquired, within the Laboratory Products and Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS for approximately $834 million in net cash consideration. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of the acquisition is not tax deductible. On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company, for approximately $406 million in net cash consideration and contingent consideration with an initial fair value of $65 million due upon the completion of certain milestones. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of the acquisition is not tax deductible. In addition, in the first three months of 2021 the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets and, also within the Life Sciences Solutions segment, an Ireland-based life sciences distributor. The components of the purchase prices and the preliminary allocations to the net assets acquired for 2021 acquisitions are as follows: (In millions) European Viral Vector Business Mesa Biotech Other Purchase Price Cash paid $ 853 $ 420 $ 107 Fair value of contingent consideration — 65 97 Cash acquired (19) (14) (4) $ 834 $ 471 $ 200 Net Assets Acquired Current assets $ 40 $ 54 $ 8 Property, plant and equipment 39 2 1 Definite-lived intangible assets: Customer relationships 311 — 3 Product technology 26 263 110 Tradenames — 2 2 Goodwill 593 248 83 Other assets 19 3 1 Contract liabilities (59) — (1) Deferred tax liabilities (82) (68) — Other liabilities assumed (53) (33) (7) $ 834 $ 471 $ 200 The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 14 years for customer relationships, 6 years for product technology and 3 years for tradenames. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 9 years. The preliminary allocations of the purchase price for the acquisitions of the European viral vector business and Mesa Biotech were based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization, largely with respect to acquired intangible assets and deferred taxes. Measurements of these items inherently require significant estimates and assumptions.

Revenue and Contract-related Ba

Revenue and Contract-related Balances	3 Months Ended
	Apr. 03, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenues and Contract-related Balances Disaggregated Revenues Revenues by type are as follows: Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues Consumables $ 5,964 $ 3,379 Instruments 1,892 1,251 Services 2,050 1,600 Consolidated revenues $ 9,906 $ 6,230 Revenues by geographic region based on customer location are as follows: Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues North America $ 5,101 $ 3,287 Europe 2,785 1,649 Asia-Pacific 1,709 1,118 Other regions 311 176 Consolidated revenues $ 9,906 $ 6,230 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of April 3, 2021 was $13.29 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 74% of which is expected to occur within the next twelve months. Contract-related Balances Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: April 3, December 31, (In millions) 2021 2020 Current Contract Assets, Net $ 783 $ 731 Noncurrent Contract Assets, Net 10 11 Current Contract Liabilities 1,396 1,271 Noncurrent Contract Liabilities 760 763 In the three months ended April 3, 2021, the company recognized revenues of $566 million that were included in the contract liabilities balance at December 31, 2020. In the three months ended March 28, 2020, the company recognized revenues of $405 million that were included in the contract liabilities balance at December 31, 2019.

Business Segment and Geographic

Business Segment and Geographical Information	3 Months Ended
	Apr. 03, 2021
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information Business Segment Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues Life Sciences Solutions $ 4,203 $ 1,774 Analytical Instruments 1,387 1,101 Specialty Diagnostics 1,615 958 Laboratory Products and Services 3,597 2,730 Eliminations (896) (333) Consolidated revenues 9,906 6,230 Segment Income Life Sciences Solutions 2,279 675 Analytical Instruments 272 171 Specialty Diagnostics 428 236 Laboratory Products and Services 531 295 Subtotal reportable segments 3,510 1,377 Cost of revenues charges (8) (2) Selling, general and administrative charges (16) (6) Restructuring and other costs (14) (38) Amortization of acquisition-related intangible assets (423) (425) Consolidated operating income 3,049 906 Interest income 12 36 Interest expense (125) (126) Other (expense) income (183) 12 Income before income taxes $ 2,753 $ 828 Geographical Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues (a) United States $ 4,892 $ 3,139 China 775 464 Other 4,239 2,627 Consolidated revenues $ 9,906 $ 6,230 (a) Revenues are attributed to countries based on customer location.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 5. Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended April 3, March 28, (In millions) 2021 2020 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 578 $ 174 Increases (Decreases) Resulting From: Foreign rate differential (55) (88) Income tax credits (89) (26) Global intangible low-taxed income 20 20 Foreign-derived intangible income (60) (17) Excess tax benefits from stock options and restricted stock units (28) (28) State income taxes, net of federal tax 49 9 Other, net 1 (4) Provision for Income Taxes $ 416 $ 40 The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. Unrecognized Tax Benefits As of April 3, 2021, the company had $1.11 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 Balance at Beginning of Year $ 1,091 Additions for tax positions of current year 8 Additions for tax positions of prior years 15 Balance at End of Period $ 1,114

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 03, 2021
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 6. Earnings per Share Three Months Ended April 3, March 28, (In millions except per share amounts) 2021 2020 Net Income $ 2,337 $ 788 Basic Weighted Average Shares 394 397 Plus Effect of: Stock options and restricted stock units 3 3 Diluted Weighted Average Shares 397 400 Basic Earnings per Share $ 5.93 $ 1.99 Diluted Earnings per Share $ 5.88 $ 1.97 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 1 1

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	3 Months Ended
	Apr. 03, 2021
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 7. Debt and Other Financing Arrangements Effective Interest Rate at April 3, April 3, December 31, (Dollars in millions) 2021 2021 2020 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) $ — $ 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.95 % 1,176 1,222 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.42 % 940 977 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 752 782 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 823 855 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.67 % 589 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.98 % 706 733 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 940 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 706 733 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 823 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 1,100 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,058 1,099 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.56 % 706 733 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 823 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,058 1,099 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,176 1,222 Other 17 12 Total Borrowings at Par Value 18,843 21,926 Fair Value Hedge Accounting Adjustments — 25 Unamortized Discount (93) (102) Unamortized Debt Issuance Costs (105) (114) Total Borrowings at Carrying Value 18,645 21,735 Less: Short-term Obligations and Current Maturities 4 2,628 Long-term Obligations $ 18,641 $ 19,107 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 10 for fair value information pertaining to the company’s long-term obligations. In connection with the agreement to acquire PPD (Note 2), the company obtained, but does not currently expect to utilize, up to $9.5 billion of committed financing. The company intends to finance the purchase price with cash on hand and the net proceeds from issuance of debt. The company is currently evaluating future debt financings and the timing of such transactions is subject to market and other conditions. Credit Facilities The company has a revolving credit facility (the Facility) with a bank group that provides for up to $3.00 billion of unsecured multi-currency revolving credit. The Facility expires on December 4, 2025. The revolving credit agreement calls for interest at either a LIBOR-based rate (or LIBOR successor rate), a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of April 3, 2021, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $31 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of April 3, 2021, there were no outstanding borrowings under these programs. Senior Notes Interest is payable annually on the euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at April 3, 2021.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Apr. 03, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 8. Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At April 3, 2021, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2020 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company's 2020 financial statements and notes included in the company's Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At April 3, 2021, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2020 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Strategic Partnership and Long-term Lease In May 2020, the company entered a strategic partnership with CSL Limited (CSL). Through a long-term lease agreement with CSL, the company will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in the second half of 2021, to perform pharma services for CSL with capacity to serve other customers as well. The company made an initial lease payment of $50 million in the second quarter of 2020 (included within other assets in the accompanying balance sheet) and expects to make additional fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent on the extent of revenues from customers of the facility other than CSL.

Comprehensive Income

Comprehensive Income	3 Months Ended
	Apr. 03, 2021
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 9. Comprehensive Income Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 224 — 6 230 Amounts reclassified from accumulated other comprehensive items — 13 2 15 Net other comprehensive items 224 13 8 245 Balance at April 3, 2021 $ (2,214) $ (78) $ (270) $ (2,562)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	3 Months Ended
	Apr. 03, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 10. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of April 3, 2021 and December 31, 2020: April 3, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 3,957 $ 3,957 $ — $ — Investments in common stock, mutual funds and other similar instruments 22 22 — — Warrants 19 — 19 — Insurance contracts 159 — 159 — Derivative contracts 121 — 121 — Total Assets $ 4,278 $ 3,979 $ 299 $ — Liabilities Derivative contracts $ 11 $ — $ 11 $ — Contingent consideration 227 — — 227 Total Liabilities $ 238 $ — $ 11 $ 227 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments in common stock, mutual funds and other similar instruments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total Assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total Liabilities $ 202 $ — $ 132 $ 70 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones), of the contingent consideration. Three Months Ended April 3, March 28, (In millions) 2021 2020 Contingent Consideration Beginning Balance $ 70 $ 55 Acquisitions (including assumed balances) 162 — Payments (7) (1) Changes in fair value included in earnings 2 — Ending Balance $ 227 $ 54 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. April 3, December 31, (In millions) 2021 2020 Notional Amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 4,517 5,206 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities April 3, December 31, April 3, December 31, (In millions) 2021 2020 2021 2020 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 2 — 9 46 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 119 3 2 86 Total Derivatives $ 121 $ 28 $ 11 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability April 3, December 31, April 3, December 31, (In millions) 2021 2020 2021 2020 Long-term Obligations $ — $ 1,020 $ — $ 25 Gain (Loss) Recognized Three Months Ended April 3, March 28, (In millions) 2021 2020 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other income (expense) $ 25 $ (36) Derivatives designated as hedging instruments - included in other income (expense) (3) 36 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (81) Amount reclassified from accumulated other comprehensive items to other expense (17) (2) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 466 83 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 38 9 Included in other income (expense) 2 5 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 12 3 Included in other income (expense) 183 40 Cross-currency interest rate swaps Included in other income (expense) — (10) Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2020 included in the company's Annual Report on Form 10-K and Note 7 herein for additional information on the company's risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt obligations are as follows: April 3, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 18,628 $ 20,530 $ 21,723 $ 24,653 Other 17 17 12 12 $ 18,645 $ 20,547 $ 21,735 $ 24,665 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Apr. 03, 2021
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 11. Supplemental Cash Flow Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Non-cash Investing and Financing Activities Acquired but unpaid property, plant and equipment $ 181 $ 83 Fair value of acquisition contingent consideration 162 — Declared but unpaid dividends 104 88 Issuance of stock upon vesting of restricted stock units 88 73 Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: April 3, December 31, (In millions) 2021 2020 Cash and Cash Equivalents $ 5,583 $ 10,325 Restricted Cash Included in Other Current Assets 19 10 Restricted Cash Included in Other Assets 1 1 Cash, Cash Equivalents and Restricted Cash $ 5,603 $ 10,336 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs

Restructuring and Other Costs	3 Months Ended
	Apr. 03, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 12. Restructuring and Other Costs In the first three months of 2021 the company recorded restructuring and other costs primarily associated with charges for compensation contractually due to employees of acquired businesses at the date of acquisition, third-party transaction/integration costs related to recent acquisitions, and charges for the sale of inventories revalued at the date of acquisition. In the first three months of 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 0.1% of the company’s workforce. As of May 7, 2021, the company has identified restructuring actions that will result in additional charges of approximately $40 million, primarily in 2021, and expects to identify additional actions during 2021 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. During the first three months of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 8 $ 10 $ 13 $ 31 Analytical Instruments — — 3 3 Specialty Diagnostics — (2) — (2) Laboratory Products and Services — 8 (3) 5 Corporate — — 1 1 $ 8 $ 16 $ 14 $ 38 The principal components of net restructuring and other costs (income) by segment are as follows: Life Sciences Solutions In the first three months of 2021, the Life Sciences Solutions segment recorded $13 million of restructuring and other costs, primarily charges for compensation contractually due to employees of acquired businesses at the date of acquisition. The segment recorded $10 million of charges to selling, general, and administrative expense, principally third-party transaction costs related to recent acquisitions. The segment also recorded $8 million of charges to cost of revenues for the sale of inventories revalued at the date of acquisition. Laboratory Products and Services In the first three months of 2021, the Laboratory Products and Services segment recorded $5 million of net restructuring and other charges, primarily for third-party transaction/integration costs related to recent acquisitions. The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2020 $ 21 Net restructuring charges incurred in 2021 (b) 3 Payments (9) Balance at April 3, 2021 $ 15 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Excludes $11 million of net charges, principally for compensation contractually due and paid to employees of acquired businesses at the date of acquisition. The company expects to pay accrued restructuring costs primarily through 2021.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 03, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Acquisitions (Policies)

Acquisitions (Policies)	3 Months Ended
	Apr. 03, 2021
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Apr. 03, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories [Table Text Block]	Inventories The components of inventories are as follows: April 3, December 31, (In millions) 2021 2020 Raw Materials $ 1,491 $ 1,305 Work in Process 602 540 Finished Goods 2,249 2,184 Inventories $ 4,342 $ 4,029

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Apr. 03, 2021
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The components of the purchase prices and the preliminary allocations to the net assets acquired for 2021 acquisitions are as follows: (In millions) European Viral Vector Business Mesa Biotech Other Purchase Price Cash paid $ 853 $ 420 $ 107 Fair value of contingent consideration — 65 97 Cash acquired (19) (14) (4) $ 834 $ 471 $ 200 Net Assets Acquired Current assets $ 40 $ 54 $ 8 Property, plant and equipment 39 2 1 Definite-lived intangible assets: Customer relationships 311 — 3 Product technology 26 263 110 Tradenames — 2 2 Goodwill 593 248 83 Other assets 19 3 1 Contract liabilities (59) — (1) Deferred tax liabilities (82) (68) — Other liabilities assumed (53) (33) (7) $ 834 $ 471 $ 200

Revenue and Contract-related _2

Revenue and Contract-related Balances (Tables)	3 Months Ended
	Apr. 03, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenues Revenues by type are as follows: Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues Consumables $ 5,964 $ 3,379 Instruments 1,892 1,251 Services 2,050 1,600 Consolidated revenues $ 9,906 $ 6,230 Revenues by geographic region based on customer location are as follows: Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues North America $ 5,101 $ 3,287 Europe 2,785 1,649 Asia-Pacific 1,709 1,118 Other regions 311 176 Consolidated revenues $ 9,906 $ 6,230
Contract with Customer, Asset and Liability [Table Text Block]	Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: April 3, December 31, (In millions) 2021 2020 Current Contract Assets, Net $ 783 $ 731 Noncurrent Contract Assets, Net 10 11 Current Contract Liabilities 1,396 1,271 Noncurrent Contract Liabilities 760 763

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	3 Months Ended
	Apr. 03, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues Life Sciences Solutions $ 4,203 $ 1,774 Analytical Instruments 1,387 1,101 Specialty Diagnostics 1,615 958 Laboratory Products and Services 3,597 2,730 Eliminations (896) (333) Consolidated revenues 9,906 6,230 Segment Income Life Sciences Solutions 2,279 675 Analytical Instruments 272 171 Specialty Diagnostics 428 236 Laboratory Products and Services 531 295 Subtotal reportable segments 3,510 1,377 Cost of revenues charges (8) (2) Selling, general and administrative charges (16) (6) Restructuring and other costs (14) (38) Amortization of acquisition-related intangible assets (423) (425) Consolidated operating income 3,049 906 Interest income 12 36 Interest expense (125) (126) Other (expense) income (183) 12 Income before income taxes $ 2,753 $ 828
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues Life Sciences Solutions $ 4,203 $ 1,774 Analytical Instruments 1,387 1,101 Specialty Diagnostics 1,615 958 Laboratory Products and Services 3,597 2,730 Eliminations (896) (333) Consolidated revenues 9,906 6,230 Segment Income Life Sciences Solutions 2,279 675 Analytical Instruments 272 171 Specialty Diagnostics 428 236 Laboratory Products and Services 531 295 Subtotal reportable segments 3,510 1,377 Cost of revenues charges (8) (2) Selling, general and administrative charges (16) (6) Restructuring and other costs (14) (38) Amortization of acquisition-related intangible assets (423) (425) Consolidated operating income 3,049 906 Interest income 12 36 Interest expense (125) (126) Other (expense) income (183) 12 Income before income taxes $ 2,753 $ 828
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended April 3, March 28, (In millions) 2021 2020 Revenues (a) United States $ 4,892 $ 3,139 China 775 464 Other 4,239 2,627 Consolidated revenues $ 9,906 $ 6,230 (a) Revenues are attributed to countries based on customer location.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Apr. 03, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended April 3, March 28, (In millions) 2021 2020 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 578 $ 174 Increases (Decreases) Resulting From: Foreign rate differential (55) (88) Income tax credits (89) (26) Global intangible low-taxed income 20 20 Foreign-derived intangible income (60) (17) Excess tax benefits from stock options and restricted stock units (28) (28) State income taxes, net of federal tax 49 9 Other, net 1 (4) Provision for Income Taxes $ 416 $ 40
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 Balance at Beginning of Year $ 1,091 Additions for tax positions of current year 8 Additions for tax positions of prior years 15 Balance at End of Period $ 1,114

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Apr. 03, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended April 3, March 28, (In millions except per share amounts) 2021 2020 Net Income $ 2,337 $ 788 Basic Weighted Average Shares 394 397 Plus Effect of: Stock options and restricted stock units 3 3 Diluted Weighted Average Shares 397 400 Basic Earnings per Share $ 5.93 $ 1.99 Diluted Earnings per Share $ 5.88 $ 1.97 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 1 1

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	3 Months Ended
	Apr. 03, 2021
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at April 3, April 3, December 31, (Dollars in millions) 2021 2021 2020 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) $ — $ 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.95 % 1,176 1,222 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.42 % 940 977 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 752 782 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 823 855 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.67 % 589 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.98 % 706 733 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 940 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 706 733 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 823 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 1,100 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,058 1,099 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.56 % 706 733 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 823 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,058 1,099 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,176 1,222 Other 17 12 Total Borrowings at Par Value 18,843 21,926 Fair Value Hedge Accounting Adjustments — 25 Unamortized Discount (93) (102) Unamortized Debt Issuance Costs (105) (114) Total Borrowings at Carrying Value 18,645 21,735 Less: Short-term Obligations and Current Maturities 4 2,628 Long-term Obligations $ 18,641 $ 19,107

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Apr. 03, 2021
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 224 — 6 230 Amounts reclassified from accumulated other comprehensive items — 13 2 15 Net other comprehensive items 224 13 8 245 Balance at April 3, 2021 $ (2,214) $ (78) $ (270) $ (2,562)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Apr. 03, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	April 3, 2021 and December 31, 2020: April 3, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 3,957 $ 3,957 $ — $ — Investments in common stock, mutual funds and other similar instruments 22 22 — — Warrants 19 — 19 — Insurance contracts 159 — 159 — Derivative contracts 121 — 121 — Total Assets $ 4,278 $ 3,979 $ 299 $ — Liabilities Derivative contracts $ 11 $ — $ 11 $ — Contingent consideration 227 — — 227 Total Liabilities $ 238 $ — $ 11 $ 227 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments in common stock, mutual funds and other similar instruments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total Assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total Liabilities $ 202 $ — $ 132 $ 70
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones), of the contingent consideration. Three Months Ended April 3, March 28, (In millions) 2021 2020 Contingent Consideration Beginning Balance $ 70 $ 55 Acquisitions (including assumed balances) 162 — Payments (7) (1) Changes in fair value included in earnings 2 — Ending Balance $ 227 $ 54
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. April 3, December 31, (In millions) 2021 2020 Notional Amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 4,517 5,206
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities April 3, December 31, April 3, December 31, (In millions) 2021 2020 2021 2020 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 2 — 9 46 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 119 3 2 86 Total Derivatives $ 121 $ 28 $ 11 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability April 3, December 31, April 3, December 31, (In millions) 2021 2020 2021 2020 Long-term Obligations $ — $ 1,020 $ — $ 25
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended April 3, March 28, (In millions) 2021 2020 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other income (expense) $ 25 $ (36) Derivatives designated as hedging instruments - included in other income (expense) (3) 36 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — (81) Amount reclassified from accumulated other comprehensive items to other expense (17) (2) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 466 83 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 38 9 Included in other income (expense) 2 5 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 12 3 Included in other income (expense) 183 40 Cross-currency interest rate swaps Included in other income (expense) — (10)
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s debt obligations are as follows: April 3, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 18,628 $ 20,530 $ 21,723 $ 24,653 Other 17 17 12 12 $ 18,645 $ 20,547 $ 21,735 $ 24,665 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s debt obligations are as follows: April 3, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 18,628 $ 20,530 $ 21,723 $ 24,653 Other 17 17 12 12 $ 18,645 $ 20,547 $ 21,735 $ 24,665 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Apr. 03, 2021
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Three Months Ended April 3, March 28, (In millions) 2021 2020 Non-cash Investing and Financing Activities Acquired but unpaid property, plant and equipment $ 181 $ 83 Fair value of acquisition contingent consideration 162 — Declared but unpaid dividends 104 88 Issuance of stock upon vesting of restricted stock units 88 73
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: April 3, December 31, (In millions) 2021 2020 Cash and Cash Equivalents $ 5,583 $ 10,325 Restricted Cash Included in Other Current Assets 19 10 Restricted Cash Included in Other Assets 1 1 Cash, Cash Equivalents and Restricted Cash $ 5,603 $ 10,336

Restructuring and Other Costs (

Restructuring and Other Costs (Tables)	3 Months Ended
	Apr. 03, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the first three months of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 8 $ 10 $ 13 $ 31 Analytical Instruments — — 3 3 Specialty Diagnostics — (2) — (2) Laboratory Products and Services — 8 (3) 5 Corporate — — 1 1 $ 8 $ 16 $ 14 $ 38
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2020 $ 21 Net restructuring charges incurred in 2021 (b) 3 Payments (9) Balance at April 3, 2021 $ 15 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw Materials	$ 1,491	$ 1,305
Work in Process	602	540
Finished Goods	2,249	2,184
Inventories	$ 4,342	$ 4,029

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 25, 2021	Jan. 15, 2021	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2021	May 07, 2021
Business Acquisition [Line Items]
Net Cash Consideration			$ 1,343	$ 4
Purchase Price
Fair value of contingent consideration			$ 162
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			9 years
Customer Relationships [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			14 years
Product Technology [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			6 years
Tradenames [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)			3 years
European Viral Vector Manufacturing Business
Business Acquisition [Line Items]
Net Cash Consideration		$ 834
Purchase Price
Cash paid		853
Cash acquired		(19)
Total Purchase Price		834
Net Assets Acquired [Abstract]
Current assets		40
Property, plant and equipment		39
Goodwill		593
Other assets		19
Contract Liabilities		(59)
Deferred tax liabilities		(82)
Other liabilities assumed		(53)
Net Assets Acquired		834
European Viral Vector Manufacturing Business | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		311
European Viral Vector Manufacturing Business | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		$ 26
Mesa Biotech
Business Acquisition [Line Items]
Net Cash Consideration	$ 406
Purchase Price
Cash paid	420
Fair value of contingent consideration	65
Cash acquired	(14)
Total Purchase Price	471
Net Assets Acquired [Abstract]
Current assets	54
Property, plant and equipment	2
Goodwill	248
Other assets	3
Deferred tax liabilities	(68)
Other liabilities assumed	(33)
Net Assets Acquired	471
Mesa Biotech | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	263
Mesa Biotech | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets	$ 2
Other [Member]
Purchase Price
Cash paid			$ 107
Fair value of contingent consideration			97
Cash acquired			(4)
Total Purchase Price			200
Net Assets Acquired [Abstract]
Current assets			8
Property, plant and equipment			1
Goodwill			83
Other assets			1
Contract Liabilities			(1)
Other liabilities assumed			(7)
Net Assets Acquired			200
Other [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			3
Other [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			110
Other [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 2
Subsequent Event [Member] | PPD, Inc [Member]
Business Acquisition [Line Items]
Percent of PPD's outstanding shares that have approved the proposed acquisition						60.00%
Forecast [Member] | Subsequent Event [Member] | PPD, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Share Price					$ 47.50
Purchase Price
Cash paid					$ 17,400
Debt assumed					$ 3,500

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 9,906	$ 6,230
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,101	3,287
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,785	1,649
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,709	1,118
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	311	176
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,964	3,379
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,892	1,251
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 2,050	$ 1,600

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Apr. 03, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 13,290
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-03
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	74.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Current Contract Assets, Net	$ 783		$ 731
Noncurrent Contract Assets, Net	10		11
Current Contract Liabilities	1,396		1,271
Noncurrent Contract Liabilities	760		$ 763
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 566	$ 405

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Segment Reporting Information [Line Items]
Revenues	$ 9,906	$ 6,230
Operating Income	3,049	906
Cost of revenues charges	(8)
Selling, general and administrative charges	(16)
Restructuring and other costs	(14)	(38)
Amortization of acquisition-related intangible assets	(423)	(425)
Interest Income	12	36
Interest Expense	(125)	(126)
Other (Expense) Income	(183)	12
Income before income taxes	2,753	828
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	(8)
Selling, general and administrative charges	(10)
Restructuring and other costs	(13)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs	(3)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges	2
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges	(8)
Restructuring and other costs	3
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	3,510	1,377
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	4,203	1,774
Operating Income	2,279	675
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues	1,387	1,101
Operating Income	272	171
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	1,615	958
Operating Income	428	236
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues	3,597	2,730
Operating Income	531	295
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues	(896)	(333)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	(8)	(2)
Selling, general and administrative charges	(16)	(6)
Restructuring and other costs	(14)	(38)
Amortization of acquisition-related intangible assets	$ (423)	$ (425)

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 9,906	$ 6,230
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	4,892	3,139
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	775	464
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 4,239	$ 2,627
[1]	Revenues are attributed to countries based on customer location.

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate	21.00%	21.00%
Provision for Income Taxes at Statutory Rate	$ 578	$ 174
Foreign rate differential	(55)	(88)
Income tax credits	(89)	(26)
Global intangible low-taxed income	20	20
Foreign-derived intangible income	(60)	(17)
Excess tax benefits from stock options and restricted stock units	(28)	(28)
State income taxes, net of federal tax	49	9
Other, net	1	(4)
Provision for Income Taxes	$ 416	$ 40

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	3 Months Ended
	Apr. 03, 2021USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at Beginning of Year	$ 1,091
Additions for tax positions of current year	8
Additions for tax positions of prior years	15
Balance at End of Period	$ 1,114

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Earnings Per Share [Abstract]
Net income	$ 2,337	$ 788
Basic Weighted Average Shares	394	397
Effect of Stock Options and Restricted Units	3	3
Diluted Weighted Average Shares	397	400
Basic Earnings Per Share (in dollars per share)	$ 5.93	$ 1.99
Diluted Earnings Per Share (in dollars per share)	$ 5.88	$ 1.97
Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	1	1

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 18,843		$ 21,926
Fair Value Hedge Accounting Adjustments			25
Unamortized Discount	(93)		(102)
Unamortized Debt Issuance Costs	(105)		(114)
Total Borrowings at Carrying Value	18,645		21,735
Less: Short-term Obligations and Current Maturities	4		2,628
Long-term Obligations	18,641		19,107
Losses on Extinguishment of Debt	197	$ 0
Proceeds from Hedge, Financing Activities	22
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 18,628		21,723
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Total Borrowings at Par Value			611
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Total Borrowings at Par Value			1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Total Borrowings at Par Value			1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.95%
Total Borrowings at Par Value	$ 1,176		1,222
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.125%
Debt Instrument, Term	5 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2025
Effective Interest Rate	0.42%
Total Borrowings at Par Value	$ 940		977
Senior Notes [Member] | 4.133% 5-Year Senior Notes, Due 3/25/2025
Debt Instrument [Line Items]
Stated Interest Rate	4.133%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Mar. 25, 2025
Effective Interest Rate	4.32%
Total Borrowings at Par Value	$ 1,100		1,100
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total Borrowings at Par Value	$ 752		782
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350		350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 823		855
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200		1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.67%
Total Borrowings at Par Value	$ 589		611
Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.75%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2027
Effective Interest Rate	1.98%
Total Borrowings at Par Value	$ 706		733
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.50%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Mar. 1, 2028
Effective Interest Rate	0.78%
Total Borrowings at Par Value	$ 940		977
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 706		733
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 823		855
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Stated Interest Rate	2.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Oct. 1, 2029
Effective Interest Rate	2.74%
Total Borrowings at Par Value	$ 900		900
Senior Notes [Member] | 4.497% 10-Year Senior Notes, Due 3/25/2030
Debt Instrument [Line Items]
Stated Interest Rate	4.497%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 25, 2030
Effective Interest Rate	5.31%
Total Borrowings at Par Value	$ 1,100		1,100
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	0.875%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 1, 2031
Effective Interest Rate	1.14%
Total Borrowings at Par Value	$ 1,058		1,099
Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Apr. 15, 2032
Effective Interest Rate	2.56%
Total Borrowings at Par Value	$ 706		733
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 823		855
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 1, 2039
Effective Interest Rate	1.73%
Total Borrowings at Par Value	$ 1,058		1,099
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400		400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate	1.875%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 1, 2049
Effective Interest Rate	1.99%
Total Borrowings at Par Value	$ 1,176		1,222
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	17		12
Total Borrowings at Carrying Value	$ 17		$ 12

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	3 Months Ended
	Apr. 03, 2021USD ($)	Apr. 15, 2021USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity	$ 3,000,000,000
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3.5
Line of Credit Facility, Amount Outstanding	$ 0
Letters of Credit Outstanding, Amount	31,000,000
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Debt	$ 0
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days
Bridge Loan [Member] | Subsequent Event [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity		$ 9,500,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 27, 2020	Apr. 03, 2021
Commitments and Contingencies Disclosure [Abstract]
Prepayment For Lease, Leases Not Yet Commenced	$ 50
Lessee, Lease Liability Payments Due, Leases Not Yet Commenced		$ 555

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 34,507	$ 29,675
Other comprehensive items before reclassifications	230
Amounts reclassified from accumulated other comprehensive items	15
Total other comprehensive items	245	(409)
Balance	35,058	28,559
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,438)
Other comprehensive items before reclassifications	224
Total other comprehensive items	224
Balance	(2,214)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(91)
Amounts reclassified from accumulated other comprehensive items	13
Total other comprehensive items	13
Balance	(78)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(278)
Other comprehensive items before reclassifications	6
Amounts reclassified from accumulated other comprehensive items	2
Total other comprehensive items	8
Balance	(270)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,807)	(2,679)
Total other comprehensive items	245	(409)
Balance	$ (2,562)	$ (3,088)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Assets [Abstract]
Cash equivalents	$ 3,957	$ 8,971
Investments in common stock, mutual funds and other similar instruments	22	21
Warrants	19	7
Insurance contracts	159	157
Derivative contracts	121	28
Total Assets	4,278	9,184
Liabilities [Abstract]
Derivative contracts	11	132
Contingent consideration	227	70
Total Liabilities	238	202
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	3,957	8,971
Investments in common stock, mutual funds and other similar instruments	22	21
Total Assets	3,979	8,992
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	19	7
Insurance contracts	159	157
Derivative contracts	121	28
Total Assets	299	192
Liabilities [Abstract]
Derivative contracts	11	132
Total Liabilities	11	132
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	227	70
Total Liabilities	$ 227	$ 70

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 70	$ 55
Acquisitions (including assumed balances)	162
Payments	(7)	(1)
Changes in fair value included in earnings	2
Ending Balance	$ 227	$ 54
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]	Selling, general and administrative expenses

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		$ 25
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge		1,020
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		25
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets		25
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives		1,000
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 2
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	9	46
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	4,517	5,206
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	119	3
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	2	86
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	121	28
Derivative Liabilities	$ 11	$ 132

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020
Cross Currency Interest Rate Contract [Member] | Other Income (Expense) [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net		$ (10)
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 12	3
Currency Exchange Contracts [Member] | Other Income (Expense) [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	183	40
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Hedged long-term obligations in Fair Value Hedge	25	(36)
Gain (Loss) on Derivative, Net	(3)	36
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in OCI on Cash Flow Hedge		(81)
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Reclassified from AOCI	(17)	(2)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	466	83
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	38	9
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 2	$ 5

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Apr. 03, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ 20,547	$ 24,665
Long-term Debt	18,645	21,735
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	20,530	24,653
Long-term Debt	18,628	21,723
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	17	12
Long-term Debt	$ 17	$ 12

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2021	Mar. 28, 2020	Dec. 31, 2020	Dec. 31, 2019
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	$ 181	$ 83
Fair value of contingent consideration	162
Declared but unpaid dividends	104	88
Issuance of stock upon vesting of restricted stock units	88	73
Cash and Cash Equivalents	5,583		$ 10,325
Restricted Cash Included in Other Current Assets	19		10
Restricted Cash Included in Other Assets	1		1
Cash, Cash Equivalents and Restricted Cash	$ 5,603	$ 3,010	$ 10,336	$ 2,422
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	Other Assets

Restructuring and Other Costs_2

Restructuring and Other Costs (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2021	Mar. 28, 2020	May 07, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated less than		0.10%
Cost of Revenues		$ 8
Selling, General and Administrative Expenses		16
Restructuring and other costs		14	$ 38
Total Restructuring and Other Costs (Income)		38
Restructuring and Related Costs, Cash Costs	[1],[2]	3
Restructuring and Related Costs, Other Costs (Income)		11
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		8
Selling, General and Administrative Expenses		10
Restructuring and other costs		13
Total Restructuring and Other Costs (Income)		31
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs		3
Total Restructuring and Other Costs (Income)		3
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		(2)
Total Restructuring and Other Costs (Income)		(2)
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		8
Restructuring and other costs		(3)
Total Restructuring and Other Costs (Income)		5
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs		1
Total Restructuring and Other Costs (Income)		$ 1
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs				$ 40
[1]	Excludes $11 million of net charges, principally for compensation contractually due and paid to employees of acquired businesses at the date of acquisition.
[2]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	3 Months Ended
	Apr. 03, 2021USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 21	[1]
Net restructuring charges incurred in 2021 (b)	3	[1],[2]
Payments	(9)	[1]
Ending balance	15	[1]
Restructuring and Related Costs, Other Costs (Income)	$ 11
Restructuring Reserve, Expected Final Year of Payments	2021
[1]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
[2]	Excludes $11 million of net charges, principally for compensation contractually due and paid to employees of acquired businesses at the date of acquisition.